JP2010502576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502576A5 JP2010502576A5 JP2009525630A JP2009525630A JP2010502576A5 JP 2010502576 A5 JP2010502576 A5 JP 2010502576A5 JP 2009525630 A JP2009525630 A JP 2009525630A JP 2009525630 A JP2009525630 A JP 2009525630A JP 2010502576 A5 JP2010502576 A5 JP 2010502576A5
- Authority
- JP
- Japan
- Prior art keywords
- fluorophenyl
- alkyl
- purin
- dihydro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000001424 substituent group Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 239000011780 sodium chloride Substances 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- -1 amino, hydroxy Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000005236 alkanoylamino group Chemical group 0.000 claims 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 102100009263 TRPV1 Human genes 0.000 claims 4
- 108060008565 TRPV1 Proteins 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000005842 heteroatoms Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 150000005215 alkyl ethers Chemical class 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- LLBLFQITYLTANI-UHFFFAOYSA-N 1-(4-bromophenyl)-9-methyl-2-(2,3,4-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Br)=CC=3)=O)=C1N=C2OC1=CC=C(F)C(F)=C1F LLBLFQITYLTANI-UHFFFAOYSA-N 0.000 claims 1
- UFDHZKZCLGSHCD-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,3-difluorophenoxy)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=CC(F)=C1F UFDHZKZCLGSHCD-UHFFFAOYSA-N 0.000 claims 1
- GJXOUFXYDLIAPY-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-difluorophenoxy)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(F)C=C1F GJXOUFXYDLIAPY-UHFFFAOYSA-N 0.000 claims 1
- NVZKVRSPSHMFOP-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[2-fluoro-3-(trifluoromethyl)phenoxy]-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=CC(C(F)(F)F)=C1F NVZKVRSPSHMFOP-UHFFFAOYSA-N 0.000 claims 1
- BICXCCNCLGHDTK-UHFFFAOYSA-N 1-(4-chlorophenyl)-9-methyl-2-(2,3,4-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(F)C(F)=C1F BICXCCNCLGHDTK-UHFFFAOYSA-N 0.000 claims 1
- GOCBGUTZCMCBQY-UHFFFAOYSA-N 1-(4-chlorophenyl)-9-methyl-2-(2,3,5-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC(F)=CC(F)=C1F GOCBGUTZCMCBQY-UHFFFAOYSA-N 0.000 claims 1
- RDZATZYARLCMSW-UHFFFAOYSA-N 1-(4-chlorophenyl)-9-methyl-2-(2,3,6-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=C(F)C=CC(F)=C1F RDZATZYARLCMSW-UHFFFAOYSA-N 0.000 claims 1
- YEOTUUZZHCYVRA-UHFFFAOYSA-N 1-(4-chlorophenyl)-9-methyl-2-(2,4,5-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC(F)=C(F)C=C1F YEOTUUZZHCYVRA-UHFFFAOYSA-N 0.000 claims 1
- KZKMCTARWGFOMA-UHFFFAOYSA-N 1-(4-chlorophenyl)-9-methyl-2-(2,4,6-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=C(F)C=C(F)C=C1F KZKMCTARWGFOMA-UHFFFAOYSA-N 0.000 claims 1
- RLANIOOGDDLPAC-UHFFFAOYSA-N 1-(4-chlorophenyl)-9-methyl-2-(3,4,5-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC(F)=C(F)C(F)=C1 RLANIOOGDDLPAC-UHFFFAOYSA-N 0.000 claims 1
- GGWKXPRZXGXJFP-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[2-fluoro-3-(trifluoromethyl)phenoxy]-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=CC(C(F)(F)F)=C1F GGWKXPRZXGXJFP-UHFFFAOYSA-N 0.000 claims 1
- VUUIPVONBOEDKY-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[3-fluoro-5-(trifluoromethyl)phenoxy]-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC(F)=CC(C(F)(F)F)=C1 VUUIPVONBOEDKY-UHFFFAOYSA-N 0.000 claims 1
- XUVCWSPRHKGBNO-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-(2,3,4-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(F)C(F)=C1F XUVCWSPRHKGBNO-UHFFFAOYSA-N 0.000 claims 1
- KQWWMJUVKWGELV-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-(2,3,5-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC(F)=CC(F)=C1F KQWWMJUVKWGELV-UHFFFAOYSA-N 0.000 claims 1
- MSQALPUSJZKFKD-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-(2,3,6-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=C(F)C=CC(F)=C1F MSQALPUSJZKFKD-UHFFFAOYSA-N 0.000 claims 1
- YNOXTIRZIPKHIO-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-(2,4,5-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC(F)=C(F)C=C1F YNOXTIRZIPKHIO-UHFFFAOYSA-N 0.000 claims 1
- FRXPIJUPJPPPDR-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-(2,4,6-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=C(F)C=C(F)C=C1F FRXPIJUPJPPPDR-UHFFFAOYSA-N 0.000 claims 1
- PWZBGSFKNLUUNT-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methyl-2-[3-(trifluoromethyl)phenoxy]purin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=CC(C(F)(F)F)=C1 PWZBGSFKNLUUNT-UHFFFAOYSA-N 0.000 claims 1
- FJJUGCOHLVRVFB-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)-9-methyl-2-(3,4,5-trifluorophenoxy)purin-6-one Chemical compound CN1C=NC(C(N2C=3C=NC(Cl)=CC=3)=O)=C1N=C2OC1=CC(F)=C(F)C(F)=C1 FJJUGCOHLVRVFB-UHFFFAOYSA-N 0.000 claims 1
- CPSVKYHUCAUTDU-UHFFFAOYSA-N 2,3-difluoro-4-[1-(4-fluorophenyl)-9-methyl-6-oxopurin-2-yl]oxybenzonitrile Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(C#N)C(F)=C1F CPSVKYHUCAUTDU-UHFFFAOYSA-N 0.000 claims 1
- XZCQLTBHLKVBAN-UHFFFAOYSA-N 2-(2,3-difluoro-4-methoxyphenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound FC1=C(F)C(OC)=CC=C1OC(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1N=CN2C XZCQLTBHLKVBAN-UHFFFAOYSA-N 0.000 claims 1
- WJMYENCITRBGSP-UHFFFAOYSA-N 2-(2,3-difluoro-4-methoxyphenoxy)-9-ethyl-1-(4-fluorophenyl)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(OC)C(F)=C1F WJMYENCITRBGSP-UHFFFAOYSA-N 0.000 claims 1
- XLSGYAGDGZHLHT-UHFFFAOYSA-N 2-(2,3-difluorophenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=CC(F)=C1F XLSGYAGDGZHLHT-UHFFFAOYSA-N 0.000 claims 1
- UHDWEXDYGOACOY-UHFFFAOYSA-N 2-(2,3-difluorophenoxy)-9-ethyl-1-(4-fluorophenyl)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=CC(F)=C1F UHDWEXDYGOACOY-UHFFFAOYSA-N 0.000 claims 1
- WZOFQUHLSGPGHX-UHFFFAOYSA-N 2-(2,3-dimethoxyphenoxy)-3-(4-fluorophenyl)-7-methylthieno[3,2-d]pyrimidin-4-one Chemical compound COC1=CC=CC(OC=2N(C(=O)C=3SC=C(C)C=3N=2)C=2C=CC(F)=CC=2)=C1OC WZOFQUHLSGPGHX-UHFFFAOYSA-N 0.000 claims 1
- WAQKDZPJBDTUCK-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound CC1=CC=CC(OC=2N(C(=O)C=3N=CN(C)C=3N=2)C=2C=CC(F)=CC=2)=C1C WAQKDZPJBDTUCK-UHFFFAOYSA-N 0.000 claims 1
- FZWKTYDFBPTNOQ-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(F)C=C1F FZWKTYDFBPTNOQ-UHFFFAOYSA-N 0.000 claims 1
- FPBJTJQJJNNKEY-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-3-(4-fluorophenyl)pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1OC1=CC=C(F)C=C1F FPBJTJQJJNNKEY-UHFFFAOYSA-N 0.000 claims 1
- GFDNJODKLFEYSI-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-9-ethyl-1-(4-fluorophenyl)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(F)C=C1F GFDNJODKLFEYSI-UHFFFAOYSA-N 0.000 claims 1
- RFRJIHXTWHXQAC-UHFFFAOYSA-N 2-(2,6-dimethylphenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound CC1=CC=CC(C)=C1OC(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1N=CN2C RFRJIHXTWHXQAC-UHFFFAOYSA-N 0.000 claims 1
- YIDJRIWMXNYOOR-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenoxy)-1-(4-chlorophenyl)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(F)C=C1Cl YIDJRIWMXNYOOR-UHFFFAOYSA-N 0.000 claims 1
- ZSNJAAODDRZQFC-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(F)C=C1Cl ZSNJAAODDRZQFC-UHFFFAOYSA-N 0.000 claims 1
- AHYQPSBHKGSOMR-UHFFFAOYSA-N 2-(2-ethylphenoxy)-3-(4-fluorophenyl)-7-methylthieno[3,2-d]pyrimidin-4-one Chemical compound CCC1=CC=CC=C1OC(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1SC=C2C AHYQPSBHKGSOMR-UHFFFAOYSA-N 0.000 claims 1
- WVRFPTNMPIUVFK-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenoxy)-1-(4-chlorophenyl)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(Cl)C=C1F WVRFPTNMPIUVFK-UHFFFAOYSA-N 0.000 claims 1
- HCHBCCNMLUGNOW-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenoxy)-1-(4-fluorophenyl)-9-methylpurin-6-one Chemical compound CN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(Cl)C=C1F HCHBCCNMLUGNOW-UHFFFAOYSA-N 0.000 claims 1
- KZSYEPGGCPVYAL-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenoxy)-3-(4-chlorophenyl)-7-methylthieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(Cl)C=C1F KZSYEPGGCPVYAL-UHFFFAOYSA-N 0.000 claims 1
- FGYQTRYWHUDUDA-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenoxy)-3-(4-fluorophenyl)-7-methylthieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(Cl)C=C1F FGYQTRYWHUDUDA-UHFFFAOYSA-N 0.000 claims 1
- ZHWDTJJJCIHRGN-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenoxy)-9-ethyl-1-(4-fluorophenyl)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(Cl)C=C1F ZHWDTJJJCIHRGN-UHFFFAOYSA-N 0.000 claims 1
- GBFFMBKVGDEOHP-UHFFFAOYSA-N 2-[2-chloro-3-(trifluoromethyl)phenoxy]-3-(4-fluorophenyl)pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1OC1=CC=CC(C(F)(F)F)=C1Cl GBFFMBKVGDEOHP-UHFFFAOYSA-N 0.000 claims 1
- SACYJCHHAPQMPK-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(2,4-difluorophenoxy)-7-methylthieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(F)C=C1F SACYJCHHAPQMPK-UHFFFAOYSA-N 0.000 claims 1
- RFUCQTHPQJOHGC-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-methyl-2-(2,3,4-trifluorophenoxy)thieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(F)C(F)=C1F RFUCQTHPQJOHGC-UHFFFAOYSA-N 0.000 claims 1
- NJLGBHPLSGFDKK-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(2,3,4-trifluorophenoxy)pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1OC1=CC=C(F)C(F)=C1F NJLGBHPLSGFDKK-UHFFFAOYSA-N 0.000 claims 1
- JBIVVRAWCUSPHV-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(2-methoxyphenoxy)-7-methylthieno[3,2-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1OC(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1SC=C2C JBIVVRAWCUSPHV-UHFFFAOYSA-N 0.000 claims 1
- YIVVXNSLCGHZIL-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1OC1=CC=CC(C(F)(F)F)=C1 YIVVXNSLCGHZIL-UHFFFAOYSA-N 0.000 claims 1
- VAMUHCUEEDHZDW-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-[3-fluoro-5-(trifluoromethyl)phenoxy]pyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C2=NC=CC=C2N=C1OC1=CC(F)=CC(C(F)(F)F)=C1 VAMUHCUEEDHZDW-UHFFFAOYSA-N 0.000 claims 1
- XYZXKEWGWJOOSN-UHFFFAOYSA-N 3-(4-fluorophenyl)-4-oxo-2-(2,3,4-trifluorophenoxy)thieno[3,2-d]pyrimidine-7-carbonitrile Chemical compound C1=CC(F)=CC=C1N1C(=O)C(SC=C2C#N)=C2N=C1OC1=CC=C(F)C(F)=C1F XYZXKEWGWJOOSN-UHFFFAOYSA-N 0.000 claims 1
- WMLCRYBHDOYZJL-UHFFFAOYSA-N 3-(4-fluorophenyl)-7-methyl-2-(2,3,4-trifluorophenoxy)thieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(F)C(F)=C1F WMLCRYBHDOYZJL-UHFFFAOYSA-N 0.000 claims 1
- RIOAPNVMXKCLEW-UHFFFAOYSA-N 3-(4-fluorophenyl)-7-methyl-2-(2,3,6-trifluorophenoxy)thieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=C(F)C=CC(F)=C1F RIOAPNVMXKCLEW-UHFFFAOYSA-N 0.000 claims 1
- QTMBRBSSNJTNGF-UHFFFAOYSA-N 3-(4-fluorophenyl)-7-methyl-2-(2-methylphenoxy)thieno[3,2-d]pyrimidin-4-one Chemical compound CC1=CSC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=CC=C1C QTMBRBSSNJTNGF-UHFFFAOYSA-N 0.000 claims 1
- YGWQIEKABHIJRY-UHFFFAOYSA-N 3-(4-fluorophenyl)-7-methyl-2-(2-propan-2-ylphenoxy)thieno[3,2-d]pyrimidin-4-one Chemical compound CC(C)C1=CC=CC=C1OC(N(C1=O)C=2C=CC(F)=CC=2)=NC2=C1SC=C2C YGWQIEKABHIJRY-UHFFFAOYSA-N 0.000 claims 1
- DLAFBAQFGNLNEJ-UHFFFAOYSA-N 4-[1-(4-chlorophenyl)-9-methyl-6-oxopurin-2-yl]oxy-2,3-difluorobenzonitrile Chemical compound CN1C=NC(C(N2C=3C=CC(Cl)=CC=3)=O)=C1N=C2OC1=CC=C(C#N)C(F)=C1F DLAFBAQFGNLNEJ-UHFFFAOYSA-N 0.000 claims 1
- IXXIYWUTSLQSCH-UHFFFAOYSA-N 5-(2,3-difluorophenoxy)-6-(4-fluorophenyl)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC=CC(F)=C1F IXXIYWUTSLQSCH-UHFFFAOYSA-N 0.000 claims 1
- CFGLPOQFUNXGMV-UHFFFAOYSA-N 5-(4-chloro-2-fluorophenoxy)-6-(4-fluorophenyl)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC=C(Cl)C=C1F CFGLPOQFUNXGMV-UHFFFAOYSA-N 0.000 claims 1
- KSPPZGPPNFWIHH-UHFFFAOYSA-N 5-[2-chloro-3-(trifluoromethyl)phenoxy]-6-(4-fluorophenyl)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC=CC(C(F)(F)F)=C1Cl KSPPZGPPNFWIHH-UHFFFAOYSA-N 0.000 claims 1
- FQFYZSSPEVHPPD-UHFFFAOYSA-N 5-[9-methyl-6-oxo-2-(3,4,5-trifluorophenoxy)purin-1-yl]pyridine-2-carbonitrile Chemical compound CN1C=NC(C(N2C=3C=NC(=CC=3)C#N)=O)=C1N=C2OC1=CC(F)=C(F)C(F)=C1 FQFYZSSPEVHPPD-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- ORALMELEOIFCMK-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-(2,3,4-trifluorophenoxy)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC=C(F)C(F)=C1F ORALMELEOIFCMK-UHFFFAOYSA-N 0.000 claims 1
- JFXLIBJAUXDMIE-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-(2,3,5-trifluorophenoxy)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC(F)=CC(F)=C1F JFXLIBJAUXDMIE-UHFFFAOYSA-N 0.000 claims 1
- GCVMRYFQUYQJIF-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-(2,4,5-trifluorophenoxy)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC(F)=C(F)C=C1F GCVMRYFQUYQJIF-UHFFFAOYSA-N 0.000 claims 1
- DOBYGDXSWDMMQZ-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-(3,4,5-trifluorophenoxy)-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC(F)=C(F)C(F)=C1 DOBYGDXSWDMMQZ-UHFFFAOYSA-N 0.000 claims 1
- LAFDJQJGBQAICQ-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-[2-fluoro-3-(trifluoromethyl)phenoxy]-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC=CC(C(F)(F)F)=C1F LAFDJQJGBQAICQ-UHFFFAOYSA-N 0.000 claims 1
- HBTCRNFJSJBEHL-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-[3-(trifluoromethyl)phenoxy]-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC=CC(C(F)(F)F)=C1 HBTCRNFJSJBEHL-UHFFFAOYSA-N 0.000 claims 1
- VIGGOQWTDZWAOM-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-[3-fluoro-5-(trifluoromethyl)phenoxy]-[1,3]thiazolo[5,4-d]pyrimidin-7-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C(N=CS2)=C2N=C1OC1=CC(F)=CC(C(F)(F)F)=C1 VIGGOQWTDZWAOM-UHFFFAOYSA-N 0.000 claims 1
- GYKCVCZBZNMUGI-UHFFFAOYSA-N 9-ethyl-1-(4-fluorophenyl)-2-(2,3,4-trifluorophenoxy)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC=C(F)C(F)=C1F GYKCVCZBZNMUGI-UHFFFAOYSA-N 0.000 claims 1
- UPSOAYOVDVWBKT-UHFFFAOYSA-N 9-ethyl-1-(4-fluorophenyl)-2-(2,3,5-trifluorophenoxy)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC(F)=CC(F)=C1F UPSOAYOVDVWBKT-UHFFFAOYSA-N 0.000 claims 1
- CCHPTVIQGBXOHD-UHFFFAOYSA-N 9-ethyl-1-(4-fluorophenyl)-2-(2,4,5-trifluorophenoxy)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=CC(F)=C(F)C=C1F CCHPTVIQGBXOHD-UHFFFAOYSA-N 0.000 claims 1
- ASXJGOFAPOIRQH-UHFFFAOYSA-N 9-ethyl-1-(4-fluorophenyl)-2-(2,4,6-trifluorophenoxy)purin-6-one Chemical compound CCN1C=NC(C(N2C=3C=CC(F)=CC=3)=O)=C1N=C2OC1=C(F)C=C(F)C=C1F ASXJGOFAPOIRQH-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 1
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010020039 Hiccups Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010027304 Menopausal symptom Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 239000006002 Pepper Substances 0.000 claims 1
- 235000016761 Piper aduncum Nutrition 0.000 claims 1
- 235000017804 Piper guineense Nutrition 0.000 claims 1
- 240000000129 Piper nigrum Species 0.000 claims 1
- 235000008184 Piper nigrum Nutrition 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000003915 air pollution Methods 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 230000003435 bronchoconstrictive Effects 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 229930003833 capsaicin Natural products 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (19)
- 式:
Arは、それぞれがハロゲン、シアノ、アミノ、ニトロ、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6ハロアルキル、C1−C6ヒドロキシアルキル、C1−C6アルコキシ、C1−C6ハロアルコキシ、(C3−C7シクロアルキル)C0−C4アルキル、及びモノ−又はジ−(C1−C6アルキル)アミノから独立して選ばれる0〜4個の置換基で置換されている、フェニル又は5員又は6員のヘテロアリールであり;そして
R3は、ハロゲン、ヒドロキシ、シアノ、アミノ、ニトロ、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6ハロアルキル、C1−C6ヒドロキシアルキル、C1−C6アルコキシ、C1−C6ハロアルコキシ、(C3−C7シクロアルキル)C0−C4アルキル、モノ−又はジ−(C1−C6アルキル)アミノ、及びモノ−又はジ−(C1−C6アルキル)アミノスルホニルから独立して選ばれる0〜4個の置換基を表す):
の化合物、又はその薬学的に許容される塩若しくは水和物。 - 化合物が式:
Xは、N、又はR1で表される置換基で置換されていてもよいCHであり;
R1は、ハロゲン、シアノ、アミノ、ニトロ、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6ハロアルキル、C1−C6ヒドロキシアルキル、C1−C6アルコキシ、C1−C6ハロアルコキシ、(C3−C7シクロアルキル)C0−C4アルキル、及びモノ−又はジ−(C1−C6アルキル)アミノから独立して選ばれる0〜3個の置換基を表し;そして
R3は、ハロゲン、ヒドロキシ、シアノ、アミノ、ニトロ、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6ハロアルキル、C1−C6ヒドロキシアルキル、C1−C6アルコキシ、C1−C6ハロアルコキシ、(C3−C7シクロアルキル)C0−C4アルキル、モノ−又はジ−(C1−C6アルキル)アミノ、及びモノ−又はジ−(C1−C6アルキル)アミノスルホニルから独立して選ばれる0〜3個の置換基を表す):
を有している、請求項1に記載の化合物、又はその塩若しくは水和物。 - R1が、ハロゲン、シアノ、C1−C4アルキル及びC1−C4ハロアルキルから独立して選ばれる1〜3個の置換基を表す、請求項2〜6の何れか一項に記載の化合物、又はその塩若しくは水和物。
- R1で表される1個の置換基が、パラ位にあるハロゲン又はシアノである、請求項7に記載の化合物、又はその塩若しくは水和物。
- R1が正確に1個の置換基を表す、請求項7又は8に記載の化合物、又はその塩若しくは水和物。
- R3が、ハロゲン、シアノ、C1−C6アルキル、C1−C6ハロアルキル及びC1−C6アルコキシから独立して選ばれる1〜3個の置換基を表す、請求項1〜9の何れか一項に記載の化合物、又はその塩若しくは水和物。
- 化合物が:
1−(4−ブロモフェニル)−9−メチル−2−(2,3,4−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−2−(2,3−ジフルオロフェノキシ)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−2−(2,4−ジフルオロフェノキシ)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−2−[2−フルオロ−3−(トリフルオロメチル)フェノキシ]−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−9−メチル−2−(2,3,4−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−9−メチル−2−(2,3,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−9−メチル−2−(2,3,6−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−9−メチル−2−(2,4,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−9−メチル−2−(2,4,6−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−クロロフェニル)−9−メチル−2−(3,4,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−2−[2−フルオロ−3−(トリフルオロメチル)フェノキシ]−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−2−[3−フルオロ−5−(トリフルオロメチル)フェノキシ]−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−9−メチル−2−(2,3,4−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−9−メチル−2−(2,3,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−9−メチル−2−(2,3,6−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−9−メチル−2−(2,4,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−9−メチル−2−(2,4,6−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
1−(4−フルオロフェニル)−9−メチル−2−[3−(トリフルオロメチル)フェノキシ]−1,9−ジヒドロ−6H−プリン−6−オン;
1−(6−クロロピリジン−3−イル)−9−メチル−2−(3,4,5−トリフルオロフェノキシ)−1H−プリン−6(9H)−オン;
2−(2,3−ジフルオロ−4−メトキシフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,3−ジフルオロ−4−メトキシフェノキシ)−9−エチル−1−(4−フルオロフェニル)−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,3−ジフルオロフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,3−ジフルオロフェノキシ)−9−エチル−1−(4−フルオロフェニル)−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,3−ジメトキシフェノキシ)−3−(4−フルオロフェニル)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
2−(2,3−ジメチルフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,4−ジフルオロフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,4−ジフルオロフェノキシ)−3−(4−フルオロフェニル)ピリド[3,2−d]ピリミジン−4(3H)−オン;
2−(2,4−ジフルオロフェノキシ)−9−エチル−1−(4−フルオロフェニル)−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2,6−ジメチルフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2−クロロ−4−フルオロフェノキシ)−1−(4−クロロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2−クロロ−4−フルオロフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(2−エチルフェノキシ)−3−(4−フルオロフェニル)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
2−(4−クロロ−2−フルオロフェノキシ)−1−(4−クロロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(4−クロロ−2−フルオロフェノキシ)−1−(4−フルオロフェニル)−9−メチル−1,9−ジヒドロ−6H−プリン−6−オン;
2−(4−クロロ−2−フルオロフェノキシ)−3−(4−クロロフェニル)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
2−(4−クロロ−2−フルオロフェノキシ)−3−(4−フルオロフェニル)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
2−(4−クロロ−2−フルオロフェノキシ)−9−エチル−1−(4−フルオロフェニル)−1,9−ジヒドロ−6H−プリン−6−オン;
2,3−ジフルオロ−4−{[1−(4−フルオロフェニル)−9−メチル−6−オキソ−6,9−ジヒドロ−1H−プリン−2−イル]オキシ}ベンゾニトリル;
2−[2−クロロ−3−(トリフルオロメチル)フェノキシ]−3−(4−フルオロフェニル)ピリド[3,2−d]ピリミジン−4(3H)−オン;
3−(4−クロロフェニル)−2−(2,4−ジフルオロフェノキシ)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
3−(4−クロロフェニル)−7−メチル−2−(2,3,4−トリフルオロフェノキシ)チエノ[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−2−(2,3,4−トリフルオロフェノキシ)ピリド[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−2−(2−イソプロピルフェノキシ)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−2−(2−メトキシフェノキシ)−7−メチルチエノ[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−2−[3−(トリフルオロメチル)フェノキシ]ピリド[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−2−[3−フルオロ−5−(トリフルオロメチル)フェノキシ]ピリド[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−4−オキソ−2−(2,3,4−トリフルオロフェノキシ)−3,4−ジヒドロチエノ[3,2−d]ピリミジン−7−カルボニトリル;
3−(4−フルオロフェニル)−7−メチル−2−(2,3,4−トリフルオロフェノキシ)チエノ[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−7−メチル−2−(2,3,6−トリフルオロフェノキシ)チエノ[3,2−d]ピリミジン−4(3H)−オン;
3−(4−フルオロフェニル)−7−メチル−2−(2−メチルフェノキシ)チエノ[3,2−d]ピリミジン−4(3H)−オン;
4−{[1−(4−クロロフェニル)−9−メチル−6−オキソ−6,9−ジヒドロ−1H−プリン−2−イル]オキシ}−2,3−ジフルオロベンゾニトリル;
5−(2,3−ジフルオロフェノキシ)−6−(4−フルオロフェニル)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
5−(4−クロロ−2−フルオロフェノキシ)−6−(4−フルオロフェニル)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
5−(9−メチル−6−オキソ−2−(3,4,5−トリフルオロフェノキシ)−6H−プリン−1(9H)−イル)ピコリノニトリル;
5−[2−クロロ−3−(トリフルオロメチル)フェノキシ]−6−(4−フルオロフェニル)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−(2,3,4−トリフルオロフェノキシ)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−(2,3,5−トリフルオロフェノキシ)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−(2,4,5−トリフルオロフェノキシ)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−(3−(トリフルオロメチル)フェノキシ)チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−(3,4,5−トリフルオロフェノキシ)[1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−[2−フルオロ−3−(トリフルオロメチル)フェノキシ][1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
6−(4−フルオロフェニル)−5−[3−フルオロ−5−(トリフルオロメチル)フェノキシ][1,3]チアゾロ[5,4−d]ピリミジン−7(6H)−オン;
9−エチル−1−(4−フルオロフェニル)−2−(2,3,4−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
9−エチル−1−(4−フルオロフェニル)−2−(2,3,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;
9−エチル−1−(4−フルオロフェニル)−2−(2,4,5−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン;又は
9−エチル−1−(4−フルオロフェニル)−2−(2,4,6−トリフルオロフェノキシ)−1,9−ジヒドロ−6H−プリン−6−オン:
である、請求項1〜14の何れか一項に記載の化合物、又はその塩若しくは水和物。 - 請求項1〜15の何れか一項に記載の化合物、又はその塩若しくは水和物の少なくとも1つを、生理学的に許容される担体又は賦形剤と共に含有してなる、医薬組成物。
- 請求項1〜15の何れか一項に記載の化合物、又はその塩若しくは水和物を有効成分として含有する、カプサイシン受容体の調節の応答に関連する疾患を治療するための医薬組成物。
- 医薬組成物が、疼痛;喘息;慢性閉塞性肺疾患;咳;しゃっくり;肥満症;更年期症状;尿失禁;過活動膀胱;カプサイシンへの暴露;熱への暴露による火傷若しくは炎症;光への暴露による火傷若しくは炎症;催涙ガス、感染病原体、大気汚染若しくは唐辛子スプレーへの暴露による火傷、気管支収縮若しくは炎症;又は酸への暴露による火傷若しくは炎症を治療するためのものである、請求項16又は17に記載の医薬組成物。
- カプサイシン受容体を、バニロイドリガンドがカプサイシン受容体に結合するのを検出可能な程度阻害するのに十分な条件下及び量で、請求項1〜15の何れか一項に記載の化合物、又はその塩若しくは水和物の少なくとも1つと接触させることを含んでなる、バニロイドリガンドがインビトロでカプサイシン受容体に結合するのを阻害する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82325806P | 2006-08-23 | 2006-08-23 | |
US60/823,258 | 2006-08-23 | ||
PCT/US2007/018654 WO2008024438A2 (en) | 2006-08-23 | 2007-08-22 | 2-phenoxy pyrimidinone analogues |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010502576A JP2010502576A (ja) | 2010-01-28 |
JP2010502576A5 true JP2010502576A5 (ja) | 2010-10-07 |
JP5421108B2 JP5421108B2 (ja) | 2014-02-19 |
Family
ID=39107411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009525630A Expired - Fee Related JP5421108B2 (ja) | 2006-08-23 | 2007-08-22 | 2−フェノキシピリミジノン類縁体 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8003656B2 (ja) |
EP (1) | EP2061794B1 (ja) |
JP (1) | JP5421108B2 (ja) |
KR (1) | KR20090043583A (ja) |
CN (2) | CN101506210A (ja) |
AU (1) | AU2007288203B2 (ja) |
BR (1) | BRPI0716582A2 (ja) |
CA (1) | CA2660957C (ja) |
CO (1) | CO6150167A2 (ja) |
CR (1) | CR10675A (ja) |
EA (1) | EA200900330A1 (ja) |
ES (1) | ES2399928T3 (ja) |
GT (1) | GT200900040A (ja) |
IL (1) | IL197043A0 (ja) |
MA (1) | MA30720B1 (ja) |
MX (1) | MX2009002066A (ja) |
NI (1) | NI200900023A (ja) |
NO (1) | NO20091182L (ja) |
SV (1) | SV2009003173A (ja) |
TW (1) | TW200825089A (ja) |
WO (1) | WO2008024438A2 (ja) |
ZA (1) | ZA200901163B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
US8003656B2 (en) | 2006-08-23 | 2011-08-23 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
SI3043784T1 (sl) * | 2013-09-09 | 2019-08-30 | Peloton Therapeutics, Inc. | Aril etri in njihova uporaba |
EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
US10155726B2 (en) | 2015-03-11 | 2018-12-18 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
WO2020146449A1 (en) * | 2019-01-08 | 2020-07-16 | Texas Tech University System | Small molecule analogs of the protein e4orf1 in the treatment and prevention of metabolic disorders |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0364598A4 (en) | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
EP0807633B1 (en) | 1996-05-15 | 2002-11-06 | Pfizer Inc. | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones |
DK0982992T3 (da) | 1997-05-08 | 2002-10-14 | Aventis Cropscience Uk Ltd | Anvendelse af thienopyrimidiner som fungicider |
US6627755B1 (en) | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
AU2002214546A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
JP2004518732A (ja) | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’2,3−dピリミジンジオン誘導体 |
JP4205430B2 (ja) | 2001-03-26 | 2009-01-07 | ノバルティス アクチエンゲゼルシャフト | 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体 |
EP1430161B1 (de) * | 2001-09-28 | 2005-06-15 | DaimlerChrysler AG | Hochfester duplex-/triplex-leichtbaustahl und seine verwendung |
WO2003055848A2 (en) | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
AU2003241453A1 (en) | 2002-05-17 | 2003-12-02 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
TW200401770A (en) | 2002-06-18 | 2004-02-01 | Sankyo Co | Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof |
WO2004028440A2 (en) | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Vr1 antagonists for the treatment of urological disorders |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
CN1894234A (zh) | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
AU2004290626A1 (en) * | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1) |
GB0326633D0 (en) | 2003-11-14 | 2003-12-17 | Merck Sharp & Dohme | Therapeutic agents |
US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
US20090298856A1 (en) | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
CN1318429C (zh) * | 2005-07-25 | 2007-05-30 | 华中师范大学 | 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3-d]嘧啶-4(3H)-酮及制备 |
WO2007056124A2 (en) | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
US8003656B2 (en) | 2006-08-23 | 2011-08-23 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
AU2007288198A1 (en) | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
EP2094704A4 (en) | 2006-11-06 | 2010-12-08 | Neurogen Corp | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES |
WO2008156607A1 (en) | 2007-06-12 | 2008-12-24 | Neurogen Corporation | Substituted pyrimidinones |
WO2009100403A1 (en) | 2008-02-07 | 2009-08-13 | Neurogen Corporation | Substituted aryl pyrimidinones |
WO2009121036A2 (en) | 2008-03-27 | 2009-10-01 | Neurogen Corporation | Substituted aryl pyrimidinone derivatives |
-
2007
- 2007-08-22 US US11/895,286 patent/US8003656B2/en active Active
- 2007-08-22 JP JP2009525630A patent/JP5421108B2/ja not_active Expired - Fee Related
- 2007-08-22 CN CNA2007800309530A patent/CN101506210A/zh active Pending
- 2007-08-22 TW TW096131019A patent/TW200825089A/zh unknown
- 2007-08-22 EA EA200900330A patent/EA200900330A1/ru unknown
- 2007-08-22 MX MX2009002066A patent/MX2009002066A/es unknown
- 2007-08-22 CN CN201410468406.2A patent/CN104292229A/zh active Pending
- 2007-08-22 CA CA2660957A patent/CA2660957C/en not_active Expired - Fee Related
- 2007-08-22 ES ES07811503T patent/ES2399928T3/es active Active
- 2007-08-22 KR KR1020097005810A patent/KR20090043583A/ko not_active Application Discontinuation
- 2007-08-22 AU AU2007288203A patent/AU2007288203B2/en not_active Ceased
- 2007-08-22 EP EP07811503A patent/EP2061794B1/en active Active
- 2007-08-22 BR BRPI0716582-0A2A patent/BRPI0716582A2/pt not_active IP Right Cessation
- 2007-08-22 WO PCT/US2007/018654 patent/WO2008024438A2/en active Application Filing
- 2007-08-22 ZA ZA200901163A patent/ZA200901163B/xx unknown
-
2009
- 2009-02-15 IL IL197043A patent/IL197043A0/en unknown
- 2009-02-20 NI NI200900023A patent/NI200900023A/es unknown
- 2009-02-20 SV SV2009003173A patent/SV2009003173A/es not_active Application Discontinuation
- 2009-02-23 GT GT200900040A patent/GT200900040A/es unknown
- 2009-03-18 CO CO09028167A patent/CO6150167A2/es unknown
- 2009-03-20 NO NO20091182A patent/NO20091182L/no not_active Application Discontinuation
- 2009-03-20 CR CR10675A patent/CR10675A/es not_active Application Discontinuation
- 2009-03-23 MA MA31732A patent/MA30720B1/fr unknown
-
2011
- 2011-08-22 US US13/215,195 patent/US8759361B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010502576A5 (ja) | ||
JP6884102B2 (ja) | がんの治療のための化合物 | |
JP5997335B2 (ja) | N含有複素環式化合物 | |
JP2007534687A5 (ja) | ||
JP2019052178A (ja) | ブロモドメイン阻害剤としての新規の置換された二環式化合物 | |
CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
JP2017526711A5 (ja) | ||
JP2010509224A5 (ja) | ||
JP2008523041A5 (ja) | ||
JP2017523223A5 (ja) | ||
RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
JP2007510689A5 (ja) | ||
JP2013523884A5 (ja) | ||
RU2006138606A (ru) | Ингибиторы киназы | |
JP2016512511A5 (ja) | ||
RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
CA2584567A1 (en) | Pyrazolo (1,5-alpha) pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists | |
JP2014528450A5 (ja) | ||
JP2009504792A5 (ja) | ||
MX2013010140A (es) | Amino-quinolinas como inhibidores de cinasa. | |
CA2737999A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | |
JP2007533707A5 (ja) | ||
JP2018515525A5 (ja) | ||
US20130096149A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors |